The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
Official Title: A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy
Study ID: NCT00083928
Brief Summary: The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of CA 125 levels.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
University of Alabama, Birmingham, Birmingham, Alabama, United States
Desert Oasis Cancer Center, Casa Grande, Arizona, United States
California Oncology of the Central Valley, Fresno, California, United States
USC Keck School of Medicine Women's and Childrens Hospital, Los Angeles, California, United States
University of California Irvine Medical Center, Orange, California, United States
UC Davis Health System, Sacramento, California, United States
Scripps Cancer Center, San Diego, California, United States
University of Colorado Cancer Center, Aurora, Colorado, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Medical College of Georgia Dept. of OB/GYN, St. Agusta, Georgia, United States
Tripler Army Medical Center, Honolulu, Hawaii, United States
Gynecologic Oncology, Hinsdale, Illinois, United States
St. Vincent Gyn-Onc, Indianapolis, Indiana, United States
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
University of Louisville JG Brown Cancer Center, Louisville, Kentucky, United States
Hematology & Oncology Specialists, New Orleans, Louisiana, United States
Barnes Jewish Hospital, St. Louis, Missouri, United States
Gabrail Cancer Center, Canton, Ohio, United States
OSU College of Medicine, Columbus, Ohio, United States
University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States
Gynecologic-Oncology Research and Development, LLC, Greenville, South Carolina, United States
Chattanooga GYN Oncology, Chattanooga, Tennessee, United States
Brooke Army Medical Center, Fort Sam Houston, Texas, United States
Carilion Gynecologic Oncology Associates, Roanoke, Virginia, United States